Evidence map›Paper›PMID 41356795›Full record

ReviewTherapeutic advances in medical oncology2025

Therapeutic opportunities in EBV-positive gastric cancer subtypes.

Hasan Al-Sattar, Richard Owen, Amir Mashia Jaafari, Abhishek Saha, Koushikk Ayyappan, Aruni Ghose, Stergios Boussios, Sola Adeleke

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hasan Al-SattarSchool of Medicine and Biomedical Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0000-0002-6830-2051
Richard OwenLudwig Institute for Cancer Research, University of Oxford, Oxford, UK.
Amir Mashia JaafariSchool of Medicine and Biomedical Sciences, University of Oxford, Oxford, UK.
Abhishek SahaSchool of Medicine and Biomedical Sciences, University of Oxford, Oxford, UK.
Koushikk AyyappanSchool of Medicine and Biomedical Sciences, University of Oxford, Oxford, UK.ORCID https://orcid.org/0009-0006-6902-5339
Aruni GhoseDepartment of Medical Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.ORCID https://orcid.org/0000-0001-8332-8033
Stergios BoussiosDepartment of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.
Sola AdelekeSchool of Biomedical Engineering and Imaging Sciences, King's College London, London WC2R 2LS, UK.ORCID https://orcid.org/0000-0002-4388-8754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has shown inconsistent results in Epstein-Barr virus-associated gastric cancer (EBVaGC) despite being associated with an active tumour microenvironment. This calls for the identification of subtypes within the EBVaGC subtype, and subsequent treatments tailored for their properties. This review identified six different EBVaGC subtypes alongside potential therapeutic opportunities. EBVaGCs, which express immune checkpoints, high microsatellite instability or high tumour mutational burden, are shown to respond better to immune checkpoint inhibitors, each due to their own specific characteristics. Co-infection of EBV and

Indexed as

EBVEBV-positive gastric cancerEpstein–Barr virusgastric cancerimmune biomarkersimmunotherapy

Identifiers

PMID41356795
PMCPMC12678741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.